Clinical Trial Update: Tislelizumab as Cross-line Treatment for Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating tislelizumab as a cross-line treatment for advanced non-small-cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Advanced Non-small-cell Lung Cancer | Phase 2 | Status: UNKNOWN